Diabeloop For Teens (DBL4T)

• ClinicalTrials.gov Identifier: NCT04725591
• Recruitment Status: Not yet recruiting
• First Posted: January 26, 2021
• Last Update Posted: January 26, 2021
• Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
• Information provided by (Responsible Party): Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

Study Description

Brief Summary:

An open-label, three-centers, controlled, randomized, and crossover study containing 14 days of baseline period with standard of care (SOC) therapy followed by two-sessions of 4-weeks home study phase with Diabeloop closed-loop (CL) system comparing the declaration of meals and the non-declaration of meals.

Condition or disease	Intervention/treatment	Phase
Closed Loop; Diabetes Mellitus, Type 1; Adolescents (12 to 17 Years Old)	Device: Dexcom G6 Continuous Glucose Monitoring; Device: Kaleïdo External Insulin Pump; Device: Diabeloop Software (Model predictive control); Other: Declaration of meals; Other: No declaration of meals; Other: Remote monitoring (Telemedicine)	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 50 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-label, Multicenter, Randomized, Crossover Study, to Assess 4 Weeks Outpatient, the Clinical Efficacy of the Diabeloop Closed-loop Glucose Control Without the Declaration of Meals Compared With the Diabeloop Closed-loop Glucose Control With the Declaration of Meals, in Adolescent Patients With Type 1 Diabetes Poorly Controlled.
• Estimated Study Start Date: February 2021
• Estimated Primary Completion Date: February 2022
• Estimated Study Completion Date: February 2022

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Diabeloop closed-loop glucose control session with the declaration of meals; Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump. Subjects are asked to declare their meals for 4 weeks. A remote monitoring system is provided in closed-loop session.	Device: Dexcom G6 Continuous Glucose Monitoring; Collection of glucose data; Device: Kaleïdo External Insulin Pump; Insulin delivery; Device: Diabeloop Software (Model predictive control); Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.; Other: Declaration of meals; Patient inputs related to meals; Other: Remote monitoring (Telemedicine); Remote follow up by care health providers team
Experimental: Diabeloop closed-loop glucose control session without the declaration of meals; Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump. Subjects are asked to not declare their meals for 4 weeks. A remote monitoring system is provided in closed-loop session.	Device: Dexcom G6 Continuous Glucose Monitoring; Collection of glucose data; Device: Kaleïdo External Insulin Pump; Insulin delivery; Device: Diabeloop Software (Model predictive control); Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.; Other: No declaration of meals; No patient inputs related to meals; Other: Remote monitoring (Telemedicine); Remote follow up by care health providers team

Outcome Measures

Primary Outcome Measures :

1. The primary outcome is the time spent of the glucose level in the widened target range 3.9-10.0 mmol/L over the 2 last weeks of each cross-over period, as recorded by continuous subcutaneous glucose monitoring (CGM). [ Time Frame: 2 weeks ]
   Measurement of glucose by CGM

Secondary Outcome Measures :

1. Incidence of severe hypoglycemia as defined by the ISPAD guidelines: [ Time Frame: 10 weeks ]
   • Number of severe hypoglycemic episodes needing a third-party intervention
   • Number of severe hypoglycemic episodes with loss of consciousness
   • Number of hospitalizations because of a severe hypoglycemia episode
   • Number of hypoglycemic episodes, defined by any crossing of the threshold of 3.33 mmol/L, 3.9 mmol/L, 3.0mmol/L and < 2.8 mmol/L measured continuous glucose monitoring.
2. • Number of severe hyperglycemia episodes with beginning and end episode as measured by the Dexcom G6 CGM [ Time Frame: 10 weeks ]
   o >19.4 mmol/L or significant ketosis (plasmatic ketones > 3 mmol/L) as defined by the ADA.
3. • Incidence of severe hyperglycemia [ Time Frame: 10 weeks ]
   o Number of events requiring an emergency room visit or hospitalizations because of ketoacidosis (i.e. incidence of DKA)
4. • Percent of CGM time with glucose < 3.9 mmol/L [ Time Frame: 10 weeks ]
   Measurement of glucose by CGM
5. • Percent of CGM time in glucose range 3.9-10.0 mmol/L [ Time Frame: 10 weeks ]
   Measurement of glucose by CGM
6. • Mean CGM glucose [ Time Frame: 10 weeks ]
   Measurement of glucose by CGM
7. • Percentage of sensor time in glucose level measured by the Dexcom G6 CGM, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am [ Time Frame: 24 hours ]
   • < 2.8 mmol/L
   • < 3.0 mmol/L
   • < 3.3 mmol/L
   • < 3.9 mmol/L
8. • Number of hypoglycemic episodes with beginning and end of episode as measured by the Dexcom G6 CGM for at least 15 minutes [ Time Frame: 10 weeks ]
   • < 3.9 mmol/L
   • < 3.0 mmol/L
   • ≤ 2.8 mmol/L
9. • Percentage of sensor time in glucose level measured by the Dexcom G6 CGM, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am [ Time Frame: 24 hours ]
   • > 10.0 mmol/L
   • > 13.9 mmol/L
   • > 16.7 mmol/L
   • > 19.4 mmol/L
10. • Number of severe hyperglycemia episodes with beginning and end of episode as measured by the Dexcom G6 CGM [ Time Frame: 10 weeks ]
    o > 19.4 mmol/L
11. • Number of serious adverse events, serious adverse device events, unanticipated adverse device effects [ Time Frame: 10 weeks ]
12. • Risk of hypoglycemia and hyperglycemia (LBGI/HBGI) [ Time Frame: 10 weeks ]
    Measurement of glucose by CGM
13. • Percentage of time spent in the 3.9-10.0 mmol/L target range, for the last 2 weeks of each cross-over session during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am [ Time Frame: 2 weeks ]
    Measurement of glucose by CGM
14. • Percentage of sensor time in glucose range 2.8 - 3.9 mmol/L, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am [ Time Frame: 24 hours ]
    Measurement of glucose by CGM
15. • Percentage of sensor time in glucose range 3.9 - 7.8 mmol/L, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am [ Time Frame: 24 hours ]
    Measurement of glucose by CGM
16. • Percentage of sensor time in glucose range 3.9 - 10.0 mmol/L, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am [ Time Frame: 24 hours ]
    Measurement of glucose by CGM
17. • Evolution of HbA1c calculated from CGM data [ Time Frame: 10 weeks ]
    Measurement of glucose by CGM
18. • Average CGM glucose level during the entire period [ Time Frame: 10 weeks ]
    Measurement of glucose by CGM
19. • Average fasting CGM glucose level at 6:00 am [ Time Frame: 10 weeks ]
    Measurement of glucose by CGM
20. • Variability of the CGM glucose level [ Time Frame: 10 weeks ]
    • the glycemic variation coefficient (CV) intra patient: CV < 36% CV ≥ 36%
    • Standard deviation (SD)
21. • Average dose of insulin used & its daily evolution during the entire study duration [ Time Frame: 10 weeks ]
22. • Number of technical incidents leading to the interruption of the closed loop [ Time Frame: 8 weeks ]
23. • Evolution over time of the DBL system's performance on a day-to-day and determination of the optimization delay of glycemic control [ Time Frame: 8 weeks ]
    Measurement of glucose by CGM
24. • Evolution of the weekly average number of CHO intake (for patient with closed-loop) [ Time Frame: 8 weeks ]
25. • Percentage of time spent in closed loop mode (i.e. DBL System with loop mode operating) [ Time Frame: 8 weeks ]
26. • Percentage of time spent in operating mode for the Dexcom G6 CGM [ Time Frame: 10 weeks ]
27. • Scoring of a questionnaire to evaluate the acceptance [ Time Frame: 10 weeks ]
    o Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a 8-item measure that enables self-reporting of the satisfaction about their current treatment. Scale is from 6 (very satisfied) to 0 (very dissatisfied).
28. • Scoring of a questionnaire to evaluate the acceptance [ Time Frame: 10 weeks ]
    o Diabetes Quality of Life (DQOL) is a 15-item questionnaire that measures diabetes care behaviors and satisfaction with diabetes control . The subject will answer by choosing from 5 suggestions : Very satisfied - Moderately satisfied - Neither - Moderately Dissatisfied - Very dissatisfied.
29. • Scoring of a questionnaire to evaluate the acceptance [ Time Frame: 10 weeks ]
    o Hypoglycemia Fear Survey (HFS) is an 8-item questionnaire that measures the fear of the risk of hypoglycemia occurring by assessing the patient's behavior towards hypoglycemia and their level of concern. Scale is from 1 to 5 (1 : Never, 2 : Rarely, 3 : Sometimes, 4: Often, 5 : Very often).
30. • Scoring of a questionnaire to evaluate the acceptance [ Time Frame: 10 weeks ]
    o Diabetes Technology Questionnaire (DTQ) aims to evaluate the impact of the closed-loop system use and diabetes specific quality of life measures in the study participants and their families, as well as satisfaction of system, as compared to conventional treatment options. The subject will answer by choosing from 5 suggestions : Strongly agree - Agree - Neither agree nor disagree - Disagree - Strongly disagree.

Eligibility Criteria

• Ages Eligible for Study: 12 Years to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Device-related inclusion criteria

• age 12 - <18 years (i.e 17 years and 364 days) at time of screening
• Type 1 diabetes Study-specific inclusion criteria
• Subject has a clinical diagnosis of type 1 diabetes for at least 1 year as determined via medical records or source documentation by an individual qualified to make a medical diagnosis or confirmed C peptide negative.
• An insulin pump user, or patient under Multiple Daily Injection (MDI), with or without CGM experience.
• Subject having a Glycosylated hemoglobin (HbA1c) blood value > 8 % at time of screening visit-based on analysis from local laboratory within 3 months.
• Living in an area covered by a GSM (Global System for Mobile Communications) network
• Patient not isolated, does not live alone, or has a person living nearby who has a telephone and a key to his or her home
• Patient willing to wear the system continuously throughout the study
• Must be able to speak and be literate in French, in Dutch or in German
• Having provided written assent & parents/guardian having provided written informed consent

Exclusion Criteria:

Device-related exclusion criteria

• Patient receiving a total daily dose of insulin lower than 8 U
• Patient having severe uncorrected problems of hearing and/or visual acuity
• Patient unable to understand and perform all of the instructions provided by Diabeloop SA Study-specific exclusion criteria
• Subject is unable to tolerate tape adhesive around the sensor or pump placements
• Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)
• Has had any of the following cardiovascular events within 1 year of screening: myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease
• Is being treated for hyperthyroidism at time of screening
• Has diagnosis of adrenal insufficiency
• Has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the study
• Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.
• Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks
• Currently abusing illicit drugs
• Currently abusing marijuana
• Currently abusing prescription drugs
• Currently abusing alcohol
• Subject is using pramlintide (Symlin), DDP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening
• Subject has elective surgery planned that requires general anesthesia during the study
• Has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
• Plans to receive red blood cell transfusion or erythropoietin over study participation
• Diagnosed with current eating disorder such as anorexia or bulimia
• Diagnosed with chronic kidney disease that results in chronic anemia
• Hematocrit that is below the normal reference range of lab used
• Patient who has had a pancreatectomy or who has pancreatic malfunctions
• Patient with pancreatic islet transplantation or pancreas transplantation
• Patient on dialysis
• Patient with impaired hepatic functions
• Serum creatinine > 176 µmol/L
• Any other physical or psychological disease, or medication likely to interfere with the conduct of the study and interpretation of the study results as judged by the investigator.
• Pregnancy or breastfeeding
• Untreated coeliac disease (2 x ULN local laboratory)
• Untreated or unstable thyroid disease

• Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any of the following during the 6 months prior to screening:

  • Medical assistance (i.e. Paramedics, Emergency Room or Hospitalization)
  • Coma
  • Seizures
• Subject having severe diabetic ketoacidosis in the 6 months prior to screening visit
• Impaired awareness of hypoglycemia (Gold Score > 4)

Contacts and Locations

No Contacts or Locations Provided

More Information

• Responsible Party: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
• ClinicalTrials.gov Identifier: NCT04725591
• Other Study ID Numbers: 2020-A02132-37
• First Posted: January 26, 2021
• Last Update Posted: January 26, 2021
• Last Verified: January 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Diabetes Mellitus, Type 1; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Insulin; Hypoglycemic Agents; Physiological Effects of Drugs